As the demands for more detailed protein characterization increase, many companies are working to meet those demands through new tools, technologies, and assays. Alistair Kippen, Ph.D., head of ...
Recombinant proteins, peptides, and antibodies could account for up to half of all new drug approvals in coming years. Meanwhile, many of the original recombinant proteins are coming off patent or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results